Log in with your email address username.


Attention doctorportal newsletter subscribers,

After December 2018, we will be moving elements from the doctorportal newsletter to MJA InSight newsletter and rebranding it to Insight+. If you’d like to continue to receive a newsletter covering the latest on research and perspectives in the medical industry, please subscribe to the Insight+ newsletter here.

As of January 2019, we will no longer be sending out the doctorportal email newsletter. The final issue of this newsletter will be distributed on 13 December 2018. Articles from this issue will be available to view online until 31 December 2018.

[Comment] Aspirin—still the GLOBAL LEADER in antiplatelet therapy

Dual antiplatelet therapy for at least a year is the standard of care after an acute coronary syndrome. Attempts to shorten the duration of therapy have resulted in an increase in myocardial infarction.1,2 Lengthening of the duration of dual antiplatelet therapy beyond a year in high-risk patients with acute coronary syndromes further reduces the risk of myocardial infarction and even ischaemic stroke.3 In patients undergoing elective percutaneous coronary intervention with current-generation drug-eluting stents, treatment guidelines recommend 6 months of dual antiplatelet therapy (or potentially longer if complex stenting is necessary).